Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045825 | 0.84 | HTT (0.49) | MAPK1KDM4EPKML3MBTL1SLC22A6 | |
| SCHEMBL5917841 | 0.83 | LCK (0.57) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL30567634 | 0.83 | LCK (0.57) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL5807186 | 0.83 | HPGDS (0.43) | KDM4ELMNAMAPTALDH1A1CYP1A2 | |
| SCHEMBL23714349 | 0.82 | MAPK1 (0.47) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL30111868 | 0.82 | MAPK1 (0.47) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL18340557 | 0.81 | MAPK1 (0.46) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL17674991 | 0.79 | KDM4E (0.46) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL30052585 | 0.79 | ALDH1A1 (0.47) | LCKMAPK1GABRPGABRDGABRA1 | |
| SCHEMBL23623861 | 0.79 | ALDH1A1 (0.47) | LCKMAPK1GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-111527078-B | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-3700902-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| EP-3786160-A1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| CN-111527078-A | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| WO-2006085199-A1 | PIPERAZINE DERIVATIVES | PFIZER LIMITED (GB) | 2006-08-17 | — | — | WO | disclosed |
| US-20050043300-A1 | Piperazine derivatives | PFIZER INC. | 2005-02-24 | — | — | US | disclosed |
| US-5891892-A | Small molecule biaryl compounds as inhibitors of endothelin converting enzyme | WARNER-LAMBERT COMPANY (US) | 1999-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169168-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | LCK 546/4885MAPK1 1059/4885GABRP 4060/4885 |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | LCK 577/4885MAPK1 1070/4885GABRP 3880/4885 |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | LCK 3440/4885MAPK1 4304/4885GABRP 1718/4885 |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | LCK 546/4885MAPK1 1059/4885GABRP 4060/4885 |
| US-20050043300-A1 | Piperazine derivatives | CD4, CCR5, RRP15 | LCK 115/4885MAPK1 1804/4885GABRP 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.